You are here

  • Home
  • Archive
  • Volume 73, Issue 7
  • Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise Report
Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)
  1. P M Meiners1,
  2. A Vissink1,
  3. F G M Kroese2,
  4. F K L Spijkervet1,
  5. N Sillevis Smitt-Kamminga3,
  6. W H Abdulahad2,
  7. J Bulthuis-Kuiper2,
  8. E Brouwer2,
  9. S Arends2,
  10. H Bootsma2
  1. 1Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  2. 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  3. 3Department of Opthalmology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  1. Correspondence to A Vissink, Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, PO-Box 30.001, Groningen 9700 RB, The Netherlands; a.vissink{at}umcg.nl

Abstract

Objective To assess the efficacy and safety of abatacept in patients with early and active primary Sjögren's syndrome (pSS).

Methods All 15 patients (12 women, three men) included in the open-label Active Sjögren Abatacept Pilot study met the revised American-European Consensus Group criteria for pSS and were biological disease-modifying antirheumatic drug-naive. Patients were treated with eight intravenous abatacept infusions on days 1, 15 and 29 and every 4 weeks thereafter. Follow-up was conducted at 4, 12, 24 (on treatment), 36 and 48 weeks (off treatment). Disease activity was assessed with European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). Several other functional, laboratory and subjective variables were analysed. Generalised estimating equations were used to analyse parameters over time.

Results ESSDAI, ESSPRI, rheumatoid factor and IgG levels decreased significantly during abatacept treatment and increased post-treatment. Salivary and lacrimal gland function did not change during treatment. Fatigue and health-related quality of life (HR-QoL) improved significantly during treatment. No serious side effects or infections were seen.

Conclusions In this open-label study, abatacept treatment is effective, safe and well tolerated, and results in improved disease activity, laboratory parameters, fatigue and HR-QoL in patients with early and active pSS.

Trial registration number 2009-015558-40.

  • Sjøgren's Syndrome
  • DMARDs (biologic)
  • Disease Activity
  • Outcomes Research
  • T Cells

https://doi.org/10.1136/annrheumdis-2013-204653

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text